Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Overview of attention for article published in Experimental Hematology & Oncology, February 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 325)
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 15 X posts from 15 X users, with an upper bound of 18,089 followers.

RT @CARTTherapy: Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy ht…

RT @CARTTherapy: Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy ht…

RT @CARTTherapy: Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy ht…

RT @CARTTherapy: Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy ht…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.